Skip to Main Content
TABLE 1

Baseline characteristics of 86 women who enrolled in the PIPOD study and completed at least one follow-up visit

VariableMean (range) ± SD
Age (years) 39 (25–54) ± 6.6 
BMI (kg/m231 (21–48) ± 4.9 
Waist-to-hip circumference ratio 0.86 (0.72–1.32) ± 0.07 
OGTT fasting plasma glucose (mg/dl)* 99 (81–124) ± 9.7 
OGTT 2-h plasma glucose (mg/dl)* 151 (97–199) ± 27.6 
OGTT glucose area (mg · dl−1 · min−1 · 10−3)* 18.3 (12.0–24.7) ± 2.8 
OGTT fasting plasma insulin (μU/ml)* 17.4 (5–64) ± 10.4 
OGTT insulin area (μU · ml−1 · min−1)* 11,058 (3,165–30,120) ± 6,662 
A1C (% of hemoglobin) 5.7 (4.4–6.6) ± 0.5 
Si (min · μU−1 · ml−1 · 10−4) 2.33 (0.37–10.90) ± 1.65 
AIRg (μU · ml−1 · min−1) 408 (−3 to 1,342) ± 292 
DI§ 834 (−2 to 2,418) ± 583 
IVGTT insulin area (μU · ml−1 · min−1) 9,654 (2,503–36,172) ± 5,743 
VariableMean (range) ± SD
Age (years) 39 (25–54) ± 6.6 
BMI (kg/m231 (21–48) ± 4.9 
Waist-to-hip circumference ratio 0.86 (0.72–1.32) ± 0.07 
OGTT fasting plasma glucose (mg/dl)* 99 (81–124) ± 9.7 
OGTT 2-h plasma glucose (mg/dl)* 151 (97–199) ± 27.6 
OGTT glucose area (mg · dl−1 · min−1 · 10−3)* 18.3 (12.0–24.7) ± 2.8 
OGTT fasting plasma insulin (μU/ml)* 17.4 (5–64) ± 10.4 
OGTT insulin area (μU · ml−1 · min−1)* 11,058 (3,165–30,120) ± 6,662 
A1C (% of hemoglobin) 5.7 (4.4–6.6) ± 0.5 
Si (min · μU−1 · ml−1 · 10−4) 2.33 (0.37–10.90) ± 1.65 
AIRg (μU · ml−1 · min−1) 408 (−3 to 1,342) ± 292 
DI§ 834 (−2 to 2,418) ± 583 
IVGTT insulin area (μU · ml−1 · min−1) 9,654 (2,503–36,172) ± 5,743 

Data are means (range) ± SD.

*

75-g OGTT; areas are total calculated by trapezoid rule.

Minimal model analysis of IVGTT results.

Incremental insulin area during the first 10 min after glucose injection.

§

Si × AIRg, a measure of β-cell compensation for insulin resistance.

Total area from 0 to 240 min. To convert values for glucose to mmol/l, multiply by 0.05551. To convert values for insulin to pmol/l, multiply by 6.0.

Close Modal

or Create an Account

Close Modal
Close Modal